TZ 60mg not included in BOGO buys or any other additional discounts

Tirzepatide – Dual Incretin Agonist
Research-Grade Peptide

Tirzepatide is a dual agonist targeting both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor. This unique mechanism of action positions it as a promising compound in the research of type 2 diabetes, obesity, and metabolic syndrome.

By simultaneously activating two key incretin pathways, Tirzepatide offers novel potential for advancing studies in glycemic control, weight management, and cardiometabolic health.

Key Research Benefits:

• Dual Incretin Agonist:
  Activates both GIP and GLP-1 receptors to regulate insulin secretion, glucose metabolism, and satiety—differentiating it from traditional GLP-1 therapies.

• Glycemic Control:
  Enhances insulin secretion, reduces glucagon release, and delays gastric emptying—supporting improved postprandial glucose regulation and insulin sensitivity.

• Weight Loss Potential:
  Promotes satiety and decreases appetite, leading to reduced caloric intake—making it highly relevant for obesity and weight-loss strategy research.

• Cardiovascular Health:
  Early studies suggest Tirzepatide may reduce blood pressure, improve lipid profiles, and benefit those with metabolic syndrome.

• Metabolic Disorder Research:
  Valuable for investigating complex conditions like insulin resistance, NAFLD, and dyslipidemia, due to its multifaceted metabolic effects.

• Long-Acting Profile:
  Once-weekly dosing allows for sustained activity and makes it ideal for longer-term studies.

Tirzepatide is a powerful tool for researchers exploring the next generation of metabolic therapies and combination incretin treatments.

For research purposes only. Not for human consumption.